EZ-editor™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With EZ-editor™, Ubigene has
successfully edited over 8000 genes on more than 300 types of cell lines.
Objective
To create a Mouse Tmem178 Knockout
model in cell line by EZ-editor™-mediated genome engineering.
Target gene info
Official symbol
Tmem178
Gene id
68027
Organism
Mus musculus
Gene type
protein-coding
Official full symbol
transmembrane protein 178
Also known as
2810417M05Rik, Tmem178a
Genomic regions
Chromosome 17
Strategy Summary
This gene has 0 protein coding transcripts:
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown.
Work flow
Ubigene - Make genome editing easier
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive EZ-editor™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on EZ-editor™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 5000+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!